Am Fam Physician. 2004 Nov 15;70(10):1862-1865.
to the editor: I enjoyed the article on the care of patients who are recovering from chemical dependency in the November 15, 2003, issue of American Family Physician.1 This important issue has received little attention in the general medical literature. The article provides an excellent overview of the special factors one should consider when treating recovering persons. Many well-meaning physicians, unaware of these considerations, have unknowingly pushed a recovering person toward relapse by prescribing an avoidable mood-altering medication. The consequences of relapse are often grave, including destroyed relationships, incarceration, and death. Understanding these issues and following the suggestions outlined by the authors can help physicians play an important role in preventing relapses.
In addition to the authors’ excellent suggestions about the management of cough in people recovering from chemical dependency, the use of albuterol inhalers should be considered. Albuterol inhalers are not mood altering, and they effectively control cough associated with bronchitis.2 In my experience, albuterol is even more effective for cough in recovering patients than it is in the general population. This is not surprising, because most recovering patients have smoking histories, and many have inhaled a wide variety of potential lung toxins (such as marijuana, cocaine, and toxins from homemade pipes made from aluminum cans).
The authors1 discuss acute pain management, but the topic of postoperative pain deserves additional attention. Following many surgical procedures, patients have no choice but to use medications that have the highest potential for triggering relapse. Recovering patients generally feel trapped between accepting the use of these substances they have worked hard to avoid or suffering unnecessarily. Physicians should reassure the patient that many thousands of persons recovering from chemical dependence have undergone major surgery and remained in recovery. The patient should be encouraged to be as active as possible in recovery effots during the perioperative period (e.g., attending 12-step meetings, meditating).
Following surgery, adequate pain relief should be provided; however, it is important not to overshoot the necessary dose because this will lead to avoidable euphoria. The physician should be attentive for objective signs of uncontrolled pain (such as vital-sign changes, apprehension, difficulty moving) and unnecessarily high doses (such as the patient nodding out during conversation or being difficult to arouse). The patient may require substantially higher doses of medication than usual, and, especially in the early recovery period, may have a very high tolerance. Because of cross-tolerance, this high tolerance may extend to substances the patient never abused.
In my experience, parenteral ketorolac (Toradol) is an effective adjunct that provides adequate relief while using much lower doses of opiates. On discharge, ongoing adequate pain relief should be provided, but the patient should be switched to non–mood-altering medications as soon as possible. Patients should be instructed to adhere precisely to the scheduled dosing of mood-altering drugs and may have someone else keep the bottle and administer the medication. If the dosage is insufficient, the patient should contact the physician to discuss increasing the dose and/or frequency. Following these suggestions can help keep patients on course with their recovery following surgery and allay many of their concerns.
1. Jones EM, Knutson D, Haines D. Common problems in patients recovering from chemical dependency. Am Fam Physician. 2003;68:1971–8.
2. Gonzales R, Sande MA. Uncomplicated acute bronchitis. Ann Intern Med. 2000;133:981–91.
editor’s note: This letter was sent to the authors of “Common Problems in Patients Recovering from Chemical Dependency,” who declined to reply.
Send letters to firstname.lastname@example.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680. Include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the AAFP permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
This series is coordinated by Kenny Lin, MD, MPH, Associate Deputy Editor for AFP Online.
Copyright © 2004 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions